Sex: U
Vaccine: COVID19, UNK, UNK
Symptoms: Hypoaesthesia, Mass, Swelling face
Clinical narrative: started to feel a lump in JW4 left side; swelling all around the lips and NL area / swelling on all mid lower face - mostly on lips, NL and C6; numbness at the NL area and nose area; This is spontaneous report from a non-contactable Healthcare professional (HCP). A patient of unspecified age and gender received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date in Jan2021 as single dose for COVID-19 immunisation; lidocaine hcl, route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication; hyaluronic acid, route of administration, start and stop date, batch/lot number and dose were not reported for an unspecified indication. The patient medical history and concomitant medications were not reported. HCP reported patient injected with 1ml of Juvederm VOLIFT with Lidocaine in the NL23, Lip1 and C6, 2ml of Juvederm VOLUX in JW1, JW4/5 and C2 and 1ml of Juvederm VOLITE in Lip8 and CK5. HCP stated, ''The result was excellent, satisfaction level high. '' Two months later, patient started to feel a lump in JW4 left side. Two weeks later patient attended the clinic for a review and HCP injected HAYALSE 200U to the area. HCP felt ''mild degradation'' and prescribed Prednisone 40mg for 5 days and Ciprofloxacin 750mg per day for 14 days. HCP advised, ''the lump got smaller but was still prominent 48 hours after injection.'' Two days later, patient felt better and continued with the prescribed medication - Prednisone for 3 days. One week later, patient presented ''swelling all around the lips and NL area and numbness at the NL area and nose area.'' Two days later, patient presented, ''worsening on swelling and lumps on injection areas - mainly NL and lips.'' Patient took 40mg of Prednisone and felt better after 6 hours. After consultation HCP decided to stop with Ciprofloxacin and start Azithromycin 500mg a day for 2 days and then 250mg for 3 more days till the next consultation. In early January, patient received the first COVID-19 PFIZER vaccination. A day later, patient presented, ''swelling on all mid lower face - mostly on lips, NL and C6." Patient did not attend the clinic and a day later, patient presented ''worsening.'' Patient attended ER for blood tests and treatment and received IV of HYdrocort 250mg. A day later, the patient showed no recovery and started to take Fexofenadine 180mg twice a day. Patient attended clinic the following day and HCP noted, all the face was with big lumps on NL, Lip1 upper lower and C8. HCP injected HAYALASE 1000U and felt a small improvement while massaging the areas. The patient started Augmentin 875mg twice a day, along with Fexofenadine. A few days later, patient received another injection of HAYALASE 1000U to the remaining stubborn lumps on same areas. HCP noted, ''improvement on swelling, but prominent lumps.'' Patient received another injection of HAYALASE 500U. HCP noted, improvement with smaller lumps remnant - no major degradation. HCP advised, ''the patient satisfaction rate for 2 months after the treatment was extremely high. Patient is frustrated obviously and want to get rid of the lumps.'' HCP further advised, ''the feeling in the tissue is a hard capsulation of the filler with minimum ability to degrade with HAYALASE. The patient improved dramatically but still with small lumps on all C8, Lips - focused and NL3.'' This record captures events relating to the Juvederm VOLIFT with Lidocaine injection. The action taken in response to the events for lidocaine hcl was unknown, for hyaluronic acid was unknown. Outcome of the event mass was not recovered, of the other events was recovering.   Pfizer is a marketing authorization holder of [lidocaine hcl] in the country of incidence or the country where the product was purchased (if different). This may be a duplicate report if another marketing authorization holder of [lidocaine hcl] has submitted the same report to the regulatory authorities.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.